David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$757M |
| 2 |
Alibaba
BABA
|
+$544M |
| 3 |
Booking.com
BKNG
|
+$475M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$377M |
| 5 |
Caterpillar
CAT
|
+$285M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.07B |
| 2 |
Amazon
AMZN
|
+$486M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$443M |
| 4 |
Salesforce
CRM
|
+$363M |
| 5 |
Qualcomm
QCOM
|
+$352M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.87% |
| 2 | Consumer Discretionary | 9.92% |
| 3 | Healthcare | 7.34% |
| 4 | Financials | 7.06% |
| 5 | Communication Services | 6.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4251
CALL
Arbor Realty Trust
ABR
$968M
| $278K | ﹤0.01% |
+15,000
| New | +$271K |
|
|
ESPR
4252
DELISTED
Esperion Therapeutics
ESPR
| $278K | ﹤0.01% |
+23,079
| New | +$336K |
|
4253
Grocery Outlet
GO
$1.19B
| $278K | ﹤0.01% |
+12,893
| New | +$371K |
|
4254
PUT
PVH
PVH
$3.44B
| $278K | ﹤0.01% |
2,700
| – | – |
|
|
SEEL
4255
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $276K | ﹤0.01% |
30
+6
| +25% | +$51.6K |
|
4256
Noodles & Co
NDLS
$93.8M
| $275K | ﹤0.01% |
2,916
-5,178
| -64% | -$507K |
|
4257
TFS Financial
TFSL
$4.97B
| $275K | ﹤0.01% |
+14,453
| New | +$282K |
|
|
NUVL
4258
DELISTED
Nuvalent
NUVL
| $274K | ﹤0.01% |
+12,142
| New | +$352K |
|
4259
SELLAS Life Sciences
SLS
$2.93B
| $274K | ﹤0.01% |
29,921
-2,193
| -7% | -$20.3K |
|
4260
SelectQuote
SLQT
$95.3M
| $273K | ﹤0.01% |
+21,112
| New | +$318K |
|
|
AAT
4261
American Assets Trust
AAT
$1.41B
| $272K | ﹤0.01% |
+7,280
| New | +$276K |
|
4262
Acumen Pharmaceuticals
ABOS
$225M
| $272K | ﹤0.01% |
+18,314
| New | +$305K |
|
|
ARGO
4263
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $272K | ﹤0.01% |
5,208
+115
| +2% | +$6.04K |
|
4264
Enpro
NPO
$6.43B
| $271K | ﹤0.01% |
3,105
| – | – |
|
4265
CRH
CRH
$63.7B
| $270K | ﹤0.01% |
5,769
-20,869
| -78% | -$1.06M |
|
4266
Mercury Insurance
MCY
$5.8B
| $270K | ﹤0.01% |
4,855
-15,150
| -76% | -$905K |
|
|
PRTK
4267
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $270K | ﹤0.01% |
55,507
-51,401
| -48% | -$283K |
|
4268
PUT
Bank of Montreal
BMO
$121B
| $269K | ﹤0.01% |
+2,700
| New | +$272K |
|
4269
Orion Group Holdings
ORN
$372M
| $268K | ﹤0.01% |
49,263
-37,255
| -43% | -$204K |
|
4270
Royal Caribbean
RCL
$78.3B
| $268K | ﹤0.01% |
3,009
-293,785
| -99% | -$23.8M |
|
|
WW
4271
DELISTED
WW International
WW
| $268K | ﹤0.01% |
14,677
+8,443
| +135% | +$221K |
|
|
CLYM
4272
Climb Bio
CLYM
$1.03B
| $268K | ﹤0.01% |
+14,912
| New | +$308K |
|
4273
Victory Capital Holdings
VCTR
$7.08B
| $267K | ﹤0.01% |
7,625
-18,664
| -71% | -$622K |
|
4274
Ducommun
DCO
$2.77B
| $266K | ﹤0.01% |
5,282
+1,096
| +26% | +$57.5K |
|
4275
Comfort Systems
FIX
$56.2B
| $266K | ﹤0.01% |
3,728
-387
| -9% | -$28.8K |
|
Similar funds
David Shaw's Q3 2021 Portfolio in Review
As of Q3 2021, David Shaw held 5,618 positions worth $111B, down 4.4% from $116B the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
David Shaw withdrew a net $8.92B in Q3 2021, closing 695 positions and reducing 1,634 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $228M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, David Shaw opened a new position in Sea Limited worth $206M.
- David Shaw's largest Q3 2021 buy was Sea Limited: 645,697 shares worth $206M.
- David Shaw added most to Activision Blizzard in Q3 2021, an estimated $757M increase.
- David Shaw's biggest Q3 2021 reduction was Apple, cutting an estimated $1.07B.
- David Shaw fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $228M.
- David Shaw's ten largest holdings make up 9.2% of its $111B portfolio in Q3 2021.
- David Shaw opened 915 new positions and closed 695 in Q3 2021.
- David Shaw's portfolio value fell 4.4% quarter-over-quarter to $111B.
Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.